Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a Phase 1, first-in-human, open-label, dose-escalation study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
Description: Number of treatment emergent adverse events as assessed by CTCAE v5.0
Measure: Incidence and severity of Treatment Emergent Adverse Events by CTCAE v5.0 Time: From screening to end of study (approximately up to 2 years) for each patientDescription: Incidence of DLTs
Measure: To characterize dose-limiting toxicities (DLTs) Time: DLT evaluation period is through cycle 1 (21 days)Description: Study drug concentration
Measure: To characterize study drug concentration Time: There are 9 blood draw collection time points at Cycles 1 and 3, 3 blood draw time points at Cycles 2,4,5 and 6, and collection at every 3 cycles after cycle 6 until end of study (approximately up to 2 years). Each cycle is 21 days.Description: Anti-drug antibody
Measure: To measure the concentration of anti-drug antibody Time: There are 2 collection time points at Cycles 1 and 3, 1 collection time point at Cycles 2, 4, 5 and 6, and and collection at every 3 cycles after cycle 6 until end of study (approximately up to 2 years). Each cycle is 21 days.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports